[SCHEDULE 13G/A] Y-mAbs Therapeutics, Inc. SEC Filing
Acorn-related investors disclosed beneficial ownership positions in Y-mAbs Therapeutics (YMAB). The filing shows Acorn Bioventures, L.P. and Acorn Capital Advisors GP, LLC each report shared voting and dispositive power over 1,175,686 shares (2.6% of the class). Acorn Bioventures 2, L.P. and its GP report shared voting and dispositive power over 1,620,611 shares (3.6%). Individually, Anders Hove is reported with shared voting and dispositive power over 2,796,297 shares, representing 6.2% of the outstanding common stock. The percentages are calculated using 45,438,420 shares outstanding as of August 4, 2025. All reporting persons are organized in Delaware except Anders Hove, a U.S. citizen. The filers certify the holdings were not acquired to influence control of the issuer.
Investitori legati ad Acorn hanno comunicato posizioni di propriet脿 beneficiaria in Y-mAbs Therapeutics (YMAB). La dichiarazione indica che Acorn Bioventures, L.P. e Acorn Capital Advisors GP, LLC detengono ciascuna poteri di voto e dispositivi condivisi su 1.175.686 azioni (2,6% della classe). Acorn Bioventures 2, L.P. e la sua GP riportano poteri di voto e dispositivi condivisi su 1.620.611 azioni (3,6%). A titolo individuale, Anders Hove risulta avere poteri di voto e dispositivi condivisi su 2.796.297 azioni, pari al 6,2% del capitale ordinario in circolazione. Le percentuali sono calcolate su 45.438.420 azioni in circolazione al 4 agosto 2025. Tutte le entit脿 dichiarante sono costituite nel Delaware, eccetto Anders Hove, cittadino statunitense. I firmatari dichiarano che le partecipazioni non sono state acquisite per influenzare il controllo dell'emittente.
Inversores vinculados a Acorn divulgaron posiciones de propiedad beneficiaria en Y-mAbs Therapeutics (YMAB). La presentaci贸n muestra que Acorn Bioventures, L.P. y Acorn Capital Advisors GP, LLC informan tener poder de voto y dispositivos compartidos sobre 1.175.686 acciones (2,6% de la clase). Acorn Bioventures 2, L.P. y su GP informan poder de voto y dispositivos compartidos sobre 1.620.611 acciones (3,6%). Individualmente, Anders Hove figura con poder de voto y dispositivos compartidos sobre 2.796.297 acciones, lo que representa el 6,2% del capital social en circulaci贸n. Los porcentajes se calculan sobre 45.438.420 acciones en circulaci贸n al 4 de agosto de 2025. Todas las personas que informan est谩n constituidas en Delaware, excepto Anders Hove, ciudadano de EE. UU. Los declarante certifican que las participaciones no se adquirieron para influir en el control del emisor.
Acorn 甏�霠� 韴瀽鞛愲摛鞚� Y-mAbs Therapeutics(YMAB)鞐� 雽�頃� 鞁れ靻岇湢 歆�攵勳潉 瓿奠嫓頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� Acorn Bioventures, L.P.鞕� Acorn Capital Advisors GP, LLC電� 臧侁皝 1,175,686欤�(頃措嫻 韥措灅鞀れ潣 2.6%)鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橂姅 瓴冹溂搿� 氤搓碃頄堨姷雼堧嫟. Acorn Bioventures 2, L.P.鞕� 攴� GP電� 1,620,611欤�(3.6%)鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤搓碃頄堨姷雼堧嫟. 臧滌澑氤勲 Anders Hove電� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 臧栯姅 2,796,297欤茧 氤搓碃霅橃棃鞙茧┌ 鞚措姅 氚滍枆 氤错喌欤检潣 6.2%鞐� 頃措嫻頃╇媹雼�. 牍勳湪鞚� 2025雲� 8鞗� 4鞚� 旮办 氚滍枆欤检嫕靾� 45,438,420欤茧ゼ 旮办鞙茧 瓿勳偘霅橃棃鞀惦媹雼�. 氇摖 氤搓碃 欤检泊電� 雿鸽澕鞗柎鞐� 靹る霅橃柎 鞛堨溂氅� Anders Hove毵� 氙戈淡 鞁滊鞛呺媹雼�. 鞝滌稖鞚鸽摛鞚� 氤挫湢 歆�攵勳澊 氚滍枆靷潣 歆�氚瓣秾鞐� 鞓來枼鞚� 欤缄赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 鞚胳頄堨姷雼堧嫟.
Des investisseurs li茅s 脿 Acorn ont divulgu茅 des positions de propri茅t茅 b茅n茅ficiaire dans Y-mAbs Therapeutics (YMAB). Le d茅p么t indique qu'Acorn Bioventures, L.P. et Acorn Capital Advisors GP, LLC d茅clarent chacune d茅tenir des pouvoirs de vote et de disposition partag茅s sur 1鈥�175鈥�686 actions (2,6 % de la cat茅gorie). Acorn Bioventures 2, L.P. et sa GP d茅clarent des pouvoirs de vote et de disposition partag茅s sur 1鈥�620鈥�611 actions (3,6 %). 脌 titre individuel, Anders Hove est signal茅 avec des pouvoirs de vote et de disposition partag茅s sur 2鈥�796鈥�297 actions, soit 6,2 % du capital social en circulation. Les pourcentages sont calcul茅s sur 45鈥�438鈥�420 actions en circulation au 4 ao没t 2025. Toutes les personnes d茅clarante sont constitu茅es dans le Delaware, 脿 l'exception d'Anders Hove, citoyen am茅ricain. Les d茅clarants certifient que les participations n'ont pas 茅t茅 acquises dans le but d'influencer le contr么le de l'茅metteur.
Investoren im Zusammenhang mit Acorn haben meldepflichtige Nutzungsrechtspositionen an Y-mAbs Therapeutics (YMAB) offengelegt. Die Einreichung zeigt, dass Acorn Bioventures, L.P. und Acorn Capital Advisors GP, LLC jeweils 眉ber gemeinsames Stimm- und Verf眉gungsrecht an 1.175.686 Aktien (2,6% der Klasse) berichten. Acorn Bioventures 2, L.P. und deren GP melden gemeinsames Stimm- und Verf眉gungsrecht an 1.620.611 Aktien (3,6%). Einzelpersonen bezogen wird Anders Hove mit gemeinsamer Stimm- und Verf眉gungsbefugnis 眉ber 2.796.297 Aktien angegeben, was 6,2% des ausstehenden Stammkapitals entspricht. Die Prozents盲tze basieren auf 45.438.420 ausstehenden Aktien zum 4. August 2025. Alle meldenden Personen sind in Delaware organisiert, mit Ausnahme von Anders Hove, der US-Staatsb眉rger ist. Die Einreichenden best盲tigen, dass die Beteiligungen nicht zum Zweck der Einflussnahme auf die Kontrolle des Emittenten erworben wurden.
- Anders Hove is reported as beneficially owning 2,796,297 shares, equal to 6.2% of outstanding common stock, a material disclosure above the 5% threshold
- Filing specifies share counts and voting/dispositive power for each reporting person, enabling transparent ownership tracking
- Percentages are calculated using a disclosed share base of 45,438,420 shares outstanding as of August 4, 2025
- None.
Insights
TL;DR: A key insider and affiliated Acorn entities report meaningful stakes; Anders Hove holds a >5% position.
The Schedule 13G/A discloses that affiliated Acorn investment vehicles collectively report material holdings in YMAB, with specific positions of 2.6% and 3.6% reported by individual funds. Notably, Anders Hove is reported with a 6.2% beneficial interest based on 45,438,420 shares outstanding, which crosses the common 5% reporting threshold and can be material for shareholder composition analysis. The filing states shared voting and dispositive power for these positions and includes the standard certification that the holdings are not intended to change control. For investors, this updates ownership concentration and insider-affiliated exposure without indicating activist intent or control-seeking activity.
TL;DR: Ownership disclosure shows a >5% beneficial owner and affiliated GP relationships; no group or control assertion.
The filing identifies structure: two Acorn limited partnerships and their GP entities, with Anders Hove as manager, resulting in reported shared voting and dispositive power across holdings. The 13G/A classification and the signed certification indicate a passive reporting status rather than an active Section 13(d) control filing. The document lists no group formation, no ownership exclusions, and reaffirms the passive intent statement. This is important for governance review because a 6.2% reported stake by an individual associated with the funds is material for ownership tables and may affect proxy dynamics, though the filer disclaims any change-of-control purpose.
Investitori legati ad Acorn hanno comunicato posizioni di propriet脿 beneficiaria in Y-mAbs Therapeutics (YMAB). La dichiarazione indica che Acorn Bioventures, L.P. e Acorn Capital Advisors GP, LLC detengono ciascuna poteri di voto e dispositivi condivisi su 1.175.686 azioni (2,6% della classe). Acorn Bioventures 2, L.P. e la sua GP riportano poteri di voto e dispositivi condivisi su 1.620.611 azioni (3,6%). A titolo individuale, Anders Hove risulta avere poteri di voto e dispositivi condivisi su 2.796.297 azioni, pari al 6,2% del capitale ordinario in circolazione. Le percentuali sono calcolate su 45.438.420 azioni in circolazione al 4 agosto 2025. Tutte le entit脿 dichiarante sono costituite nel Delaware, eccetto Anders Hove, cittadino statunitense. I firmatari dichiarano che le partecipazioni non sono state acquisite per influenzare il controllo dell'emittente.
Inversores vinculados a Acorn divulgaron posiciones de propiedad beneficiaria en Y-mAbs Therapeutics (YMAB). La presentaci贸n muestra que Acorn Bioventures, L.P. y Acorn Capital Advisors GP, LLC informan tener poder de voto y dispositivos compartidos sobre 1.175.686 acciones (2,6% de la clase). Acorn Bioventures 2, L.P. y su GP informan poder de voto y dispositivos compartidos sobre 1.620.611 acciones (3,6%). Individualmente, Anders Hove figura con poder de voto y dispositivos compartidos sobre 2.796.297 acciones, lo que representa el 6,2% del capital social en circulaci贸n. Los porcentajes se calculan sobre 45.438.420 acciones en circulaci贸n al 4 de agosto de 2025. Todas las personas que informan est谩n constituidas en Delaware, excepto Anders Hove, ciudadano de EE. UU. Los declarante certifican que las participaciones no se adquirieron para influir en el control del emisor.
Acorn 甏�霠� 韴瀽鞛愲摛鞚� Y-mAbs Therapeutics(YMAB)鞐� 雽�頃� 鞁れ靻岇湢 歆�攵勳潉 瓿奠嫓頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� Acorn Bioventures, L.P.鞕� Acorn Capital Advisors GP, LLC電� 臧侁皝 1,175,686欤�(頃措嫻 韥措灅鞀れ潣 2.6%)鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橂姅 瓴冹溂搿� 氤搓碃頄堨姷雼堧嫟. Acorn Bioventures 2, L.P.鞕� 攴� GP電� 1,620,611欤�(3.6%)鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤搓碃頄堨姷雼堧嫟. 臧滌澑氤勲 Anders Hove電� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 臧栯姅 2,796,297欤茧 氤搓碃霅橃棃鞙茧┌ 鞚措姅 氚滍枆 氤错喌欤检潣 6.2%鞐� 頃措嫻頃╇媹雼�. 牍勳湪鞚� 2025雲� 8鞗� 4鞚� 旮办 氚滍枆欤检嫕靾� 45,438,420欤茧ゼ 旮办鞙茧 瓿勳偘霅橃棃鞀惦媹雼�. 氇摖 氤搓碃 欤检泊電� 雿鸽澕鞗柎鞐� 靹る霅橃柎 鞛堨溂氅� Anders Hove毵� 氙戈淡 鞁滊鞛呺媹雼�. 鞝滌稖鞚鸽摛鞚� 氤挫湢 歆�攵勳澊 氚滍枆靷潣 歆�氚瓣秾鞐� 鞓來枼鞚� 欤缄赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 鞚胳頄堨姷雼堧嫟.
Des investisseurs li茅s 脿 Acorn ont divulgu茅 des positions de propri茅t茅 b茅n茅ficiaire dans Y-mAbs Therapeutics (YMAB). Le d茅p么t indique qu'Acorn Bioventures, L.P. et Acorn Capital Advisors GP, LLC d茅clarent chacune d茅tenir des pouvoirs de vote et de disposition partag茅s sur 1鈥�175鈥�686 actions (2,6 % de la cat茅gorie). Acorn Bioventures 2, L.P. et sa GP d茅clarent des pouvoirs de vote et de disposition partag茅s sur 1鈥�620鈥�611 actions (3,6 %). 脌 titre individuel, Anders Hove est signal茅 avec des pouvoirs de vote et de disposition partag茅s sur 2鈥�796鈥�297 actions, soit 6,2 % du capital social en circulation. Les pourcentages sont calcul茅s sur 45鈥�438鈥�420 actions en circulation au 4 ao没t 2025. Toutes les personnes d茅clarante sont constitu茅es dans le Delaware, 脿 l'exception d'Anders Hove, citoyen am茅ricain. Les d茅clarants certifient que les participations n'ont pas 茅t茅 acquises dans le but d'influencer le contr么le de l'茅metteur.
Investoren im Zusammenhang mit Acorn haben meldepflichtige Nutzungsrechtspositionen an Y-mAbs Therapeutics (YMAB) offengelegt. Die Einreichung zeigt, dass Acorn Bioventures, L.P. und Acorn Capital Advisors GP, LLC jeweils 眉ber gemeinsames Stimm- und Verf眉gungsrecht an 1.175.686 Aktien (2,6% der Klasse) berichten. Acorn Bioventures 2, L.P. und deren GP melden gemeinsames Stimm- und Verf眉gungsrecht an 1.620.611 Aktien (3,6%). Einzelpersonen bezogen wird Anders Hove mit gemeinsamer Stimm- und Verf眉gungsbefugnis 眉ber 2.796.297 Aktien angegeben, was 6,2% des ausstehenden Stammkapitals entspricht. Die Prozents盲tze basieren auf 45.438.420 ausstehenden Aktien zum 4. August 2025. Alle meldenden Personen sind in Delaware organisiert, mit Ausnahme von Anders Hove, der US-Staatsb眉rger ist. Die Einreichenden best盲tigen, dass die Beteiligungen nicht zum Zweck der Einflussnahme auf die Kontrolle des Emittenten erworben wurden.
FAQ
Who filed the Schedule 13G/A for YMAB?
How many YMAB shares does Anders Hove beneficially own?
What percentages of YMAB do the Acorn entities report?
What share count was used to calculate percentages in the filing?
Does the filing indicate an intent to change or influence control of Y-mAbs?
